Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1302 - Carbohydrate antigen 19-9 and apolipoprotein A2 isoform as early detection biomarkers for pancreatic cancer: a prospective evaluation by the EPIC study

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Kazufumi Honda

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

K. Honda1, V. Katzke2, A. Hüsing2, S. Okaya1, H. Shoji3, K. Onidani1, F. Canzian4, R. Kaaks2

Author affiliations

  • 1 Department Of Biomarkers For Early Detection Of Cancer, National Cancer Center Research Institute, 104-0045 - Tokyo/JP
  • 2 Division Of Cancer Epidemiology, German Cancer Research Center, Heidelberg/DE
  • 3 Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 4 Genomic Epidemiology, German Cancer Research Center, Heidelberg/DE
More

Resources

Abstract 1302

Background

This study prospectively evaluated the performance of an apolipoprotein A2 isoform (ApoA2-ATQ/AT) in combination with carbohydrate antigen 19-9 (CA19-9) as early detection biomarkers for pancreatic cancer.

Methods

Using ELISA, we measured CA19-9 and ApoA2-ATQ/AT in plasma samples collected ≤60 months before diagnosis from 159 pancreatic cancer patients and 217 matched controls within the EPIC (European Prospective Investigation into Cancer and Nutrition) cohort. The diagnostic sensitivity, specificity, and C-statistics were calculated for risk scores by strata of the time before diagnosis.

Results

The C-statistics of CA19-9 and CA19-9+ApoA2-ATQ/AT for distinguishing pancreatic cancer patients from cancer-free individuals were 0.87 and 0.68, respectively, for samples taken ≤6 months before diagnosis, and 0.74 and 0.72, respectively, for samples taken <6 to 18 months before diagnosis. The joint diagnostic model using CA19-9+ApoA2-ATQ/AT showed significantly improved diagnostic discrimination in samples taken ≤18 months before diagnosis. Before diagnosis, the specificity of CA19-9+ApoA2-ATQ/AT was 98%, while the sensitivities of CA19-9+ApoA2-ATQ/AT were 57%, 36%, and 43%, respectively, and those of CA19-9 alone were 50%, 29%, and 36%, respectively. This joint model also showed significantly improved C-statistics for the diagnostic discrimination of samples taken >6 to 18 months (0.80 for CA19-9+ApoA2-ATQ/AT, 0.74 for CA19-9; p = 0.004) and ≤18 months (0.8 for CA19-9+ApoA2-ATQ/AT, 0.78 for CA19-9; p = 0.003) before diagnosis.

Conclusions

Compared to CA19-9 alone, CA19-9+ApoA2-ATQ/AT showed improved diagnostic discrimination for early detection ≤18 months before diagnosis. This plasma biomarker panel may provide a useful first measure for detecting pancreatic cancer prior to imaging. We have reported those results on behalf of the EPIC Europe.

Clinical trial identification

Legal entity responsible for the study

National Cancer Center.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.